Taiwan Stock Exchange · Healthcare
Grape King Bio stock from India: price, numbers and tax
Grape King Bio (1707) is not currently available to trade on Paasa; this guide covers the price, the numbers and the Indian tax treatment.
By Paasa · Updated
Grape King Bio at a glance
- Price
- NT$85.20-NT$0.50 (0.58%)
- Market cap
- NT$12.62B
- Day range
- NT$85.20 – NT$85.60
- P/E
- 10.99
- Dividend yield
- 7.04%
- Volume
- 206.79K
- 1 month
- -4.70%
- 6 months
- -29.59%
- YTD
- -32.65%
- 1 year
- -34.46%
- 5 years
- -46.58%
Grape King Bio statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | NT$10.3B | NT$11.2B | NT$10.6B | NT$10.4B | NT$9.8B |
| Gross profit | NT$7.7B | NT$8.7B | NT$8.5B | NT$8.5B | NT$7.9B |
| Operating income | NT$2.1B | NT$2.5B | NT$2.5B | NT$2.7B | NT$2.4B |
| Net income | NT$1.2B | NT$1.4B | NT$1.5B | NT$2.2B | NT$1.9B |
| Earnings per share | NT$8.22 | NT$9.79 | NT$9.81 | NT$14.65 | NT$13.20 |
| EBITDA | NT$2.7B | NT$3.2B | NT$3.1B | NT$3.1B | NT$2.8B |
| Total assets | NT$15.7B | NT$15.3B | NT$15.5B | NT$15.1B | NT$14.1B |
| Total debt | NT$215.0M | NT$160.9M | NT$192.9M | NT$157.8M | NT$271.8M |
| Cash and short-term investments | NT$4.3B | NT$4.4B | NT$5.0B | NT$4.8B | NT$3.9B |
| Shareholders' equity | NT$10.3B | NT$10.1B | NT$10.0B | NT$9.6B | NT$9.0B |
| Operating cash flow | NT$2.2B | NT$1.9B | NT$2.5B | NT$3.0B | NT$2.5B |
| Free cash flow | NT$1.7B | NT$1.2B | NT$1.9B | NT$2.5B | NT$2.3B |
| Capital expenditure | −NT$445.5M | −NT$647.9M | −NT$601.4M | −NT$502.5M | −NT$278.4M |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in TWD; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| Handa Pharmaceuticals | 6620.TWO | $143.50 | $23.90B |
| TTY Biopharm | 4105.TWO | $78.40 | $19.49B |
| TaiMed Biologics | 4147.TWO | $61.50 | $16.65B |
| Synmosa Biopharma | 4114.TWO | $29.50 | $15.92B |
| YungShin Global | 3705.TW | NT$56.40 | NT$15.02B |
| ScinoPharm Taiwan | 1789.TW | NT$18.75 | NT$14.83B |
| Foresee Pharmaceuticals | 6576.TWO | $79.10 | $12.46B |
| Standard Chem & Pharm | 1720.TW | NT$56.10 | NT$11.03B |
Peers as grouped by the data provider. This is not an investment recommendation.
Why invest in Grape King Bio from India
What Grape King Bio does
Grape King Bio Ltd. is a Taiwanese enterprise specializing in the production and distribution of a diverse array of health-focused items, encompassing pharmaceuticals, traditional remedies, nourishing beverages, and dietary supplements. Its market presence spans Taiwan, mainland China, and various international regions. Grape King Bio operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
What tax do I pay in India when I sell Grape King Bio shares?
In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the TWD/INR rate on the day you bought and the day you sold, so the currency move is part of the gain.